This evidence is consistent with the finding that PLK1 inhibition by volasertib leads to the stabilization of the ubiquitin ligase Fbxw7 and the degradation of its downstream target N-Myc in MYCN-overexpressing neuroblastoma cells. The gene discussed is MYCN; the disease is neuroblastoma.